Theratechnologies Inc. is a specialty pharmaceutical company. The Company is engaged in the discovery and development of therapeutic peptide products, with focus on growth-hormone releasing factor (GRF) peptides. The Company�s product, EGRIFTA (tesamorelin for injection), is the therapy for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. As of November 30, 2011, the Company was marketed in the United States by EMD Serono, Inc. (EMD Serono). On January 10, 2011, EMD Serono launched EGRIFTA.